RxDoctor Payments Data

Keith Skolnick, MD

Ophthalmology · Plantation, FLNPI 1851393581

Payments from drug & device makers

$3,846in general payments, 2019–2025

Across 86 payments — averaging $44.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$2K
  • AbbVie$521
  • Mallinckrodt Hospital Products Inc.$190
  • Glaukos Corporation$132
  • Amgen$115
  • NEW World Medical,inc.$100
  • plus $862 from 17 others

What the payments were for

  • Food & beverage$1,75346%
  • Education$1684%
  • Ownership interest$1,92650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,846 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$428,882
Medicare patients
683
Services billed
2,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac128$47,055
CombiganBrimonidine Tartrate/Timolol170$38,446
ProlensaBromfenac Sodium99$34,605
RestasisCyclosporine40$31,347
Lotemax SmLoteprednol Etabonate112$27,877
Prednisolone Acetate758$23,533
LumiganBimatoprost63$23,046
XiidraLifitegrast13$21,491
BesivanceBesifloxacin Hcl87$19,067
MoxifloxacinMoxifloxacin Hcl666$12,108
Travoprost60$11,581
RocklatanNetarsudil Mesylat/Latanoprost19$11,576
Bromfenac Sodium120$10,443
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol58$9,665
Latanoprost971$7,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Restasis, Lumigan, Alphagan P$521$100,026292 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Besivance$58$81,548298 claims
NovartisIlevro$15$47,055128 claims
Bausch & Lomb Americas Inc.Xiidra$60$21,49113 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$42$19,00535 claims
AlconAzopt, Simbrinza$86$6,49322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →